ATE338768T1 - Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression - Google Patents

Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression

Info

Publication number
ATE338768T1
ATE338768T1 AT98956204T AT98956204T ATE338768T1 AT E338768 T1 ATE338768 T1 AT E338768T1 AT 98956204 T AT98956204 T AT 98956204T AT 98956204 T AT98956204 T AT 98956204T AT E338768 T1 ATE338768 T1 AT E338768T1
Authority
AT
Austria
Prior art keywords
muc
derivatives
mucin
treating cancer
induced immunosuppression
Prior art date
Application number
AT98956204T
Other languages
English (en)
Inventor
Babita Agrawal
Mark Austin Reddish
Bryan Michael Longenecker
Original Assignee
Biomira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc filed Critical Biomira Inc
Application granted granted Critical
Publication of ATE338768T1 publication Critical patent/ATE338768T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98956204T 1997-10-31 1998-10-30 Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression ATE338768T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6414697P 1997-10-31 1997-10-31
US6520997P 1997-11-12 1997-11-12

Publications (1)

Publication Number Publication Date
ATE338768T1 true ATE338768T1 (de) 2006-09-15

Family

ID=26744203

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98956204T ATE338768T1 (de) 1997-10-31 1998-10-30 Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression

Country Status (8)

Country Link
US (1) US20020159969A1 (de)
EP (1) EP1027373B1 (de)
JP (1) JP2002526380A (de)
AT (1) ATE338768T1 (de)
AU (1) AU749152B2 (de)
CA (1) CA2307622A1 (de)
DE (1) DE69835828T2 (de)
WO (1) WO1999023114A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058450A2 (en) * 2000-12-22 2002-08-01 Dana-Faber Cancer Institute, Inc. Regulation of cell growth by muc1
AU2003266236A1 (en) 2002-07-22 2004-02-09 Nemod Immuntherapie Ag Method for the production of an immunostimulating mucin (muc1)
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US7871784B2 (en) 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
LT3401402T (lt) * 2012-06-08 2020-12-28 Alkermes Pharma Ireland Limited Ligandai, modifikuoti cirkuliarinės permutacijos pagalba, kaip agonistai ir antagonistai
PT4065585T (pt) 2019-11-25 2025-09-30 Alkermes Inc Compostos macrocíclicos substituídos e métodos de tratamento relacionados
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0442926A1 (de) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptide
AU5849796A (en) * 1994-12-27 1996-08-07 United Biomedical Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
WO1996040066A1 (en) * 1995-06-07 1996-12-19 The Governors Of The University Of Alberta A METHOD FOR ELICITING A Th1-SPECIFIC IMMUNE RESPONSE
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same

Also Published As

Publication number Publication date
EP1027373A1 (de) 2000-08-16
US20020159969A1 (en) 2002-10-31
AU749152B2 (en) 2002-06-20
AU1278299A (en) 1999-05-24
DE69835828D1 (de) 2006-10-19
WO1999023114A1 (en) 1999-05-14
CA2307622A1 (en) 1999-05-14
JP2002526380A (ja) 2002-08-20
EP1027373B1 (de) 2006-09-06
DE69835828T2 (de) 2007-04-12

Similar Documents

Publication Publication Date Title
AU5057998A (en) Insoluble s-triazine derivatives and their use as uv filters
ATE196844T1 (de) Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
ATE208382T1 (de) Konjugate von cis-docosahexaensäure und paclitaxel
DE69830336D1 (de) Ein kovalentes konjugat von clozapine und einer fettsäure und dessen verwendung zur behandlung von schizophrenie
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
ATE413386T1 (de) Ppar-gamma modulatoren
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
DE59902314D1 (de) Oligomerisiertes Organopolysiloxan-Cokondensat, dessen Herstellung und dessen Verwendung zur Behandlung von Oberflächen
DE69725825D1 (de) 5-HT1F-Agonisten
ATE228502T1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
TR200200821T2 (tr) 5-Beta-sapojenin ve pseudosapojenin türevleri ve bunların bunama tedavisinde kullanımı.
UA66861C2 (uk) 2-феніл-1-[4-(2-аміноетокси)бензил]індол в комбінації з естрогенами, способи лікування та продукт для лікування
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
ATE338768T1 (de) Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties